GrowBLOX Sciences, Inc. (GBLX)
GrowBLOX Sciences, Inc. (GBLX), a biopharmaceutical research and development company, is focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies for various medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.
The company's GrowBLOX technology suite includes the TissueBLOX, GrowBLOX, and CureBLOX equipment. Together, these components provide unparalleled control and monitoring of cannabis cultivation throughout the plant's life-cycle. These patent pending processes were designed to produce a safe and consistent cannabis product under cGMP guidelines. Utilizing a computer-regulated system that optimizes the nutrients, water, temperature, and gas levels, the GrowBLOX suite produces cannabis with more active ingredients per pound than traditional cultivation methods.
Also, based on an analysis of preclinical and clinical data from thousands of peer-reviewed studies, GrowBLOX Sciences has identified the most effective profiles of cannabinoids and terpenes for the treatment of conditions within seven therapeutic categories. As a result of this extensive research and the analysis of the active ingredient profiles of 30,000 Cannabis strains in conjunction with a major testing lab, the company will be able to provide patients with natural cannabis strains containing the ideal ratios for treating specific diseases or symptoms.
Another significant advantage held by the company stems from an accelerated drug development program to finish in 3-5 years instead of the 15-20 years typically seen in traditional pharmaceutical development programs. Armed with an intellectual property strategy that takes full advantage of the design of the GrowBLOX technology suite and protects the valuable foundation laid, GrowBLOX Sciences has positioned itself well for long-term success in the burgeoning cannabis space.
